Field trip news
June 23, 2023
Stella, a leader in comprehensive treatment for post-traumatic stress injury (PTSI), anxiety, stress, depression, traumatic brain injury and the neurological effects of long COVID, announced today its acquisition of the U.S. assets of Field Trip, a global leader in the delivery of psychedelic therapies. The strategic addition broadens Stella's range of advanced treatments and strengthens its position as a premier provider of holistic, effective biological and psychological treatments.
This Continuing Education course has been designed to assist therapists in growing their understanding of what this intervention entails and whether this might be an appropriate adjunctive treatment. Instructed by Dr. Michael Verbora.
The Program, which offers people the ability to participate in ketamine therapy at-home or in one of Field Trip’s locations, is designed to increase accessibility to psychedelic-assisted therapy for those suffering from mild to moderate depression, anxiety, and trauma and support it with a holistic approach to mental health and well-being.
Psychedelics have huge potential to treat a range of mental illnesses. Field Trip Health is one of dozens of companies to leap into a sector reminiscent of the early days of the cannabis craze.
Psychedelics seem poised to help a lot of people in a lot of pain.
Oregonians will soon have a front-row seat to what researchers and enthusiasts have dubbed the “psychedelic renaissance.”
Scientists are designing new psychedelic-inspired drugs that don’t yet exist, which might have effects no one can yet describe.
A doctor and a psychologist say Health Canada’s move to allow physicians to request restricted psychedelic drugs for patients as part of their psychotherapy is a positive step toward transforming mental-health care.
We announced that we will begin making applications for Canadians in need to access psilocybin-assisted and MDMA-assisted therapy through Health Canada’s Special Access Program (SAP). This announcement followed amendments to the SAP which have enabled physicians in Canada to make applications to Health Canada for access to “restricted drugs”, including psilocybin and MDMA.
The mind-altering drug has been shown to help people suffering from anxiety and depression. But how it helps, who it will serve, and who will profit are open questions.
We're doubling down on our mission to expand to new markets and bring the power of psychedelic-assisted therapy to the mainstream, as evidenced by our latest hire: Vicki Reed, a former CMO of Peloton, is joining the company as our Chief Growth Officer.
"With ketamine clinics and psilocybin therapists and more places starting to come online, people are beginning to realize that the music part in all of this is actually really important."
At least 12 ketamine clinics are operating in the Seattle area. The clinics, which have been sprouting across North America the past couple of years, use the drug to treat mental illness.
VR looks to cover the unmet need of assisting people unfamiliar with the use of psychedelics in clinical settings.
Quick Trip: Companies like Atai and Field Trip are developing second-generation psychedelic drugs that have modified duration times in an effort to condense therapy into a two-hour window.
It's a question as old as human consciousness: what happens after we die? While we may never have a full answer, there are plenty of first-hand accounts from individuals who have perhaps touched the boundaries between life and the great unknown via near death experiences (NDEs). In this episode of Spiraling, VICE producer Zeke Spector tries to conquer his own fear of death by attempting to recreate the conditions of an NDE in order to try and understand understand what death might teach us about life itself.
Psychedelic drug therapy is gaining popularity. Lauren had a traumatic delivery of her twins and carried the trauma with her, and she is about to try her first sessions of ketamine therapy. Vice president of the Field Trip Health Care Practice Matt Emer shares what the treatment entails. Watch as Lauren undergoes this treatment and shares how she feels just afterward.
"I've had depression for years now. I finally turned to a ketamine clinic for help."
After a 25 year military career, including two tours of Afghanistan, former master corporal Scott Atkinson struggled with post-traumatic stress disorder, depression, anxiety, and chronic pain. After finding some relief in medical cannabis, he became interested in psychedelic-assisted psychotherapy. Then, he went through six sessions of ketamine therapy at our Toronto clinic. “It’s changed my life,” he says. “It’s given me a way to go now. I’m not as angry all the time. The anxiety isn’t there all the time. It’s better with my family and with my kids. A year ago I was a completely different person.”
A W5 investigation into an unconventional treatment for severe depression and PTSD that involves the drug ketamine.
Jon Hopkins timed his upcoming album to the length of a ketamine high, while apps are using AI music to tailor drug experiences. Welcome to a techno-chemical new frontier.
Housewives in the Hills are doing it. Hipsters in Los Feliz, too. L.A. has became ground zero for a new hallucinogen boom, with ayahuas ca ceremonies now as common as barbecues. But is microdosing shrooms really the answer to what ails Angelenos?
Ronan Levy, our executive chairman, speaks with Toronto life about the impact and future of psychedelic therapies.
Patrick Fletch speaks to Toronto Life about his experience with Ketamine-Assisted Psychotherapy at Field Trip Health.
Janine Bajnauth speaks to Toronto Life about her experience with Ketamine-Assisted Psychotherapy at Field Trip Health.
Psychedelics may be one of the biggest recent breakthroughs in the mental health world, and Toronto’s Field Trip Health is determined to couple it with one of the oldest treatments in the book — psychotherapy.
Doctors are looking into psychedelics to possibly reduce anxiety and depression. NBC News’ Maya Eaglin reports on the new wave of mental health care.
Depression, often characterized by feelings of worthlessness, profound apathy, exhaustion and persistent sadness, affects 320 million people around the world. In a typical year in the U.S., roughly 16 million adults, or 7 percent, suffer from a depression-related illness such as major depression, bipolar disorder or dysthymia. Roughly one-third of those who seek treatment won't respond to verbal or conventional drug therapies. Magic-mushroom therapy is offering some hope for these hopeless cases.
Psilocybin and MDMA represent a first wave of therapies that help patients by changing the way they view reality.
Scientists treating depression and a range of other mental illnesses have been running controlled trials using MDMA and psychedelic drugs such as LSD and the results have been encouraging.